RecruitingNCT04085900

Screening Nasopharyngeal Carcinoma With EBV Associated Biomarkers in Zhongshan City

Searching for Early Detection Biomarkers of Nasopharyngeal Carcinoma in Zhongshan City

Sponsor

Zhongshan People's Hospital, Guangdong, China

Enrollment

40,000 participants

Start Date

Apr 1, 2020

Study Type

OBSERVATIONAL

Conditions

Nasopharyngeal Carcinoma

Summary

All participants will be tested for EBV associated biomarkers, including EBNA1-IgA, VCA-IgA, BNLF2b total antibodies (P85-Ab) et al. For all male participants and P85-Ab positive female participants, EBV DNA in plasma will be tested. Screening positive participants will be followed up annually. All subjects will also be followed by record linkage to Cancer Register and Population Register.

Eligibility

Min Age: 30 YearsMax Age: 69 Years

Plain Language Summary

Simplified for easier understanding

This study is screening healthy residents in Zhongshan City (China) for early signs of nasopharyngeal carcinoma — a cancer that starts at the back of the nose — using blood-based biomarkers linked to the Epstein-Barr virus (EBV), which is associated with this cancer. **You may be eligible if...** - You live in Zhongshan City or Wuzhou City - You have never been diagnosed with nasopharyngeal carcinoma before - You are in generally good health and able to cooperate with follow-up **You may NOT be eligible if...** - You have serious heart, liver, or kidney disease - You have a medical reason that would prevent you from safely having a nasal endoscopy (a camera examination of the back of your nose) Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALBlood and saliva

Collect blood and saliva samples from participants

DIAGNOSTIC_TESTP85-Ab, EBNA1-IgA, VCA-IgA and EBV DNA

Detect P85-Ab, EBNA1-IgA, VCA-IgA for all participants, and detect EBV DNA for all male participants and P85-Ab positive female participants.

DIAGNOSTIC_TESTFiberoptic endoscopy and biopsy

Screening participants will refer to fiberoptic endoscopy and biospy

Locations(2)

Zhongshan People's Hospital

Zhongshan, Guangdong, China

Wuzhou Red Cross Hospital

Wuzhou, Guangxi, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04085900

Related Trials

A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors

NCT064753001 location

Induction Chemotherapy Response-Guided Radiation for EBV-Associated Nasopharyngeal Carcinoma

NCT066824421 location

Camrelizumab Plus Stereotactic Body Radiotherapy vs Camrelizumab Alone For Oligometastatic Nasopharyngeal Carcinoma

NCT049449141 location

Tislelizumab and Metronomic Capecitabine as Maintenance in High-risk Locoregionally-advanced Nasopharyngeal Carcinoma

NCT060930612 locations

Clinical Study on the EBV CAR-T /TCR-T Cells in the Treatment of Nasopharyngeal Carcinoma

NCT055875431 location